Study Summary:
Click image to enlarge
You may qualify for a clinical research study to test the effectiveness of a new investigational drug for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Diffuse large B-cell lymphoma is a type of non-Hodgkin’s lymphoma, and is relatively common.
Qualifications Include:
- Adults ages 18 and older
- Histologically confirmed aggressive B-cell DLBCL
- Not currently undergoing chemotherapy, radiotherapy, immunotherapy, biologic, investigational, or hormonal therapy for the treatment of lymphoma
- Prior unsuccessful treatment with targeted anti-CD20-based therapy combined with chemotherapy. ‘Unsuccessful’ meaning a return of the cancer or lack of response to the treatments.
Participants who qualify for this study may receive all study related care and study drug at no cost.